Associated Papers
Targeting SHOC2: a treatable therapeutic site in RAS(Q61) mutant cancers.
Tang J et al.
Science China. Life Sciences, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
Mao Y et al.
Npj Precision Oncology, 2026
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.
Bonsor DA et al.
Nature Communications, 2026
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Baars B et al.
Molecular Cancer Research : Mcr, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors.
Vergara IA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Hauseman ZJ et al.
Nature, 2025
Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases.
Vergara R et al.
Scientific Reports, 2025
Multicenter In-House Evaluation of an Amplicon-Based Next-Generation Sequencing Panel for Comprehensive Molecular Profiling.
Jantus-Lewintre E et al.
Molecular Diagnosis & Therapy, 2025
The mutational spectrum of NRAS gene discovers a novel frameshift mutation (E49R) in Saudi colorectal cancer patients.
Rasool M et al.
Cancer Cell International, 2025
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma.
Yeh CN et al.
Npj Precision Oncology, 2025
Identifying Novel Genetic Markers in Pediatric Rhabdomyosarcoma.
Xu J et al.
Journal of Pediatric Surgery, 2025
Genomic profiles and their associations with microsatellite instability status, tumor mutational burden, and programmed death ligand 1 expression in Chinese patients with colorectal cancer.
Luo B et al.
Journal of Gastrointestinal Oncology, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jiang J et al.
Cancer Discovery, 2024
RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations.
Bonsor DA et al.
Annual Review of Cancer Biology, 2024
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M et al.
Targeted Oncology, 2024
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.
Alawieh D et al.
Blood Cancer Journal, 2024
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ et al.
Nature Reviews. Clinical Oncology, 2024
Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
Bezić J et al.
Acta Dermatovenerologica Croatica : Adc, 2024
Clinical application of tumour-in-normal contamination assessment from whole genome sequencing.
Mitchell J et al.
Nature Communications, 2024
Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study.
Clavero-Rovira L et al.
Cancers, 2024
Follicular cell-derived thyroid carcinomas harboring novel genetic BRAFNON-V600E mutations: real-world data obtained using a multigene panel.
von Ammon JL et al.
Archives of Endocrinology and Metabolism, 2024
The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.
Fei M et al.
Frontiers in Oncology, 2024
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer.
Crucitta S et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.
Danielli SG et al.
Science Advances, 2023
BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
Valentín-Bravo FJ et al.
Arquivos Brasileiros De Oftalmologia, 2023
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
Haefliger S et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism.
Bajia D et al.
Cells, 2022
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
Kar SP et al.
Nature Genetics, 2022
Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel.
Sgariglia R et al.
Journal of Clinical Pathology, 2022
DrugCVar: a platform for evidence-based drug annotation for genetic variants in cancer.
Zhang X et al.
Bioinformatics (oxford, England), 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.
Garcia N et al.
Molecular Cancer Therapeutics, 2022
Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai YJ et al.
Bmc Cancer, 2021
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D et al.
The Journal of Pathology, 2021
Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.
Gkiala A et al.
Clinical Ophthalmology (auckland, N.z.), 2020
Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M et al.
Diagnostic Pathology, 2019
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Shaukat I et al.
Human Pathology, 2019
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A et al.
Plos One, 2019
Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.
Lai J et al.
Oncotargets and Therapy, 2018
Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Ye Q et al.
Chinese Medical Journal, 2017
RAS isoforms and mutations in cancer at a glance.
Hobbs GA et al.
Journal of Cell Science, 2016
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D et al.
Oncotarget, 2015
Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K et al.
Plos One, 2015
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
Birkeland E et al.
Clinical & Experimental Metastasis, 2013
Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
Case M et al.
Cancer Research, 2008